Group items tagged

Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective at preventing infections. The failure of the trial marks yet another setback in the search for a vaccine against a virus known to mutate rapidly and find unique ways to evade the immune system, and comes more than a year after another of J&J's HIV vaccine failed a study. "It's not the outcome we had hoped for, unfortunately," said a spokesperson for the National Institute of Allergy and Infectious Diseases, a J&J partner in the trial. "The development of a safe and effective HIV vaccine has been a considerable scientific challenge, but we will learn from this study and continue forward." The trial involved administering two different types of a shot, which uses a cold-causing virus to deliver the genetic code of HIV, spread over four vaccination visits in a year. J&J used similar technology for its COVID-19 vaccine. The study, which began in 2019, was conducted at over 50 sites and included about 3,900 gay men and transgender people - groups that are considered vulnerable to the infection.

Health authorities in India have said that Biological E's Covid-19 vaccine Corbevax can be administered as a booster dose in people who have taken the country's other two main shots, Covaxin and AstraZeneca's Covishield, from Friday (Aug 12). Corbevax will be available to over 18s as precautionary booster six months after a second dose, the health ministry said in an August 8 letter to state authorities. Covishield is produced for the Indian market by the Serum Institute of India under licence from AstraZeneca, while Bharat Biotech makes Covaxin. India has so far administered more than 2 billion Covid vaccine shots, including 113 million boosters, all of which have so far been of the same vaccine as the recipient's first two doses. The government says about 89 per cent of Indians above the age of 12 have had two doses.

GlaxoSmithKline and Sanofi said on Wednesday (December 15) they expect data from late-stage clinical trials of its booster dose of their Covid-19 vaccine candidate in the first quarter, instead of this year, another delay for the potential shot. The news came as two companies said preliminary data from trials showed the single-dose booster provided strong immune responses. They added that they need more time to test the booster on more people who have not been infected by the virus before they can submit data to regulators. The Phase III trial for the recombinant adjuvanted Covid-19 vaccine recruited most participants in the third quarter, coinciding with a significant increase in the number of people infected globally due to the Delta variant, it said. "To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022." No safety concerns were identified. This is the latest delay for the vaccine's development, putting the companies further behind rivals in the race for Covid-19 shots.

US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory illnesses and help improve readiness for any future pandemics. The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement. Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris Johnson to reopen the economy from stringent lockdowns. Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV). "By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be pandemic ready," Bancel said on Wednesday.

The flu vaccine is recommended for all , starting with children from 6 months age by US Centers for Disease Control and Prevention (CDC). To have a greater effect than the flu vaccine is advisable to be vaccinated immediately when vaccines are available in the fall. The objective is to sufficiently during your body to build immunity against influenza virus before flu season is in height. If your child turns 6 months old, in the middle of winter , not worry . No problem to get your flu shot, even in late January or beginning of February .

As the height of the flu season approaches, we want all of you to be maximally protected. As helpful as a flu shot is, it definitely does not provide full protection. Read more.

As the height of the flu season approaches, we want all of you to be maximally protected. As helpful as a flu shot is, it definitely does not provide full protection. Read more.

Health and social care workers in England, including those working in community pharmacy, will no longer have to have a Covid jab as a condition of employment from later this month, the government said on Tuesday (March 1). The government had announced on January 31 that it intended to revoke the regulations that made vaccination compulsory, subject to the results of a public consultation. The decision was taken because the Omicron strain of the virus was less severe than the Delta variant, and due to high rates of vaccination of people in the UK. Health secretary Sajid Javid told parliament in a written statement that more than 90,000 health and social care workers and members of the public responded to the consultation.

The Joint Committee on Vaccination and Immunisation (JCVI) on Thursday (May 19) said that an anticipated autumn Covid booster campaign would be aimed at people aged over 65, care home residents, frontline health and social care workers and all adults in a clinical risk group. The UK is offering a spring booster to the over-75s, care home residents and immunosuppressed people, and ministers have spoken openly of plans for a further booster campaign in the autumn. In interim advice, the JCVI stopped short of recommending another shot for all adults, though said the advice would be reviewed and updated. "The JCVI's current view is that in autumn 2022, a Covid-19 vaccine should be offered to: residents in a care home for older adults and staff; frontline health and social care workers; all those 65 years of age and over; and adults aged 16 to 64 years who are in a clinical risk group," the UK Health Security Agency said in a statement. Prime minister Boris Johnson, who was fiercely criticised for his handling of the early stages of the pandemic, lifted Covid restrictions in England in February, crediting Britain's quick initial vaccine rollout and the rollout of boosters with breaking the link between cases and deaths.

Putin is seeking to seal deals with India in a shot to assist resuscitate Russia's recession-hit eco...

Have you recently been diagnosed with Type 2 Diabetes, or have you been living with this disease for some time? Did you know that you can reverse your diabetes and lead a normal, healthy life free from insulin shots, and stop worrying about your blood sugar levels?

All of our physicians and medical staff members pledge to treat every single one of our patients as if they were a member of our own families.

Wouldn't it be wonderful if there was a delicious diet that could greatly reduce your risk for getting the flu? It is now recognized that the flu shot for this year's flu season (2014-2015) only provides 23% protection, and less than that if you are older than 65. A well-balanced vegetarian diet does improve immune efficiency by helping to double the number of natural killer cells (special immune cells that destroy viruses and cancer cells). Read more.

The latest tie-up involves US giant Merck. They have agreed to help produce the one-shot vaccine developed by Johnson & Johnson.

AstraZeneca said its antibody cocktail against Covid-19 would - unlike its vaccine - be priced commercially as it negotiates supply contracts with governments around the globe. "We are looking at a commercial pricing strategy. That is part of our negotiations with governments," Iskra Reic, Astra's executive vice president for vaccines and immune therapies, said in a media call on Thursday. She added that the group's main objective was to make the shot affordable and broadly available.

Britain has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva. "An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and Healthcare products Regulatory Agency said in a statement on Thursday (April 14), adding: "It is also the first, whole-virus inactivated Covid-19 vaccine to gain regulatory approval in the UK." In vaccines such as Valneva's VLA2001, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response. It is seen by some as having the potential to win over people wary of some which use new mRNA technology. Valneva CEO Thomas Lingelbach said that "this authorisation could pave the way for the availability of an alternative vaccine solution for the UK population."

As part of efforts to streamline spending and enhance resource allocation within the healthcare system, the NHS has chosen to cease providing the free vaccinations for all, which were initially introduced in 2020. Approximately 12 million British citizens will not have access to free flu vaccinations and Covid-19 boosters during the upcoming winter, according to NHS. Furthermore, the NHS plans to defer flu vaccine distribution to October, aiming to heighten protection for those aged 65 and older and other eligible groups in the high-risk winter months. However, this has stirred panic among pharmacies, given their advanced planning based on the initial start date of September 1 for vaccinations. On Tuesday (Aug. 8), the Joint Committee on Vaccination and Immunisation (JCVI) released NHS guidelines indicating that Covid-19 booster shots, starting from autumn, will not be provided to individuals aged 50 to 64 who are in otherwise good health. Similar guidance had already been released for flu, rendering 12 million middle-aged Britons ineligible for free jabs, JCVI said. Prior to the pandemic, influenza vaccinations were available to healthy adults aged over 65, alongside children and younger adults with medical conditions. Amidst the pandemic, the distribution of flu vaccinations was expanded to include individuals aged 50 to 64, in alignment with the criteria for Covid-19 boosters.

Pharmacy chain Superdrug has introduced what it asserts to be the most affordable private flu vaccinations offered on the UK high street. The vaccinations will be priced at £8.79 for 17.2 million members of its Ghada , and £16.99 for non-members. The 2023-24 vaccination service is set to become available across 150 of its stores starting from early September. Superdrug has taken this step in response to a change in NHS England's inclusion criteria, which has rendered the 12 million individuals aged 50-65 ineligible for the NHS flu vaccination service, the company said. The company is anticipating heightened demand for private flu vaccinations due to the postponed commencement of the NHS service and alterations in eligibility for free flu jabs. "Our waiting list for private flu vaccination services has already exceeded last year's figures, indicating a heightened demand this year," said Ghada Beal, Superdrug's Healthcare Director. "Providing this service at a more accessible price-point is significant, given the eligibility changes that will impact millions. Our private flu vaccination services provide a convenient means for individuals to safeguard themselves against flu and its potential complications." In May, the government's annual flu vaccination programme letter indicated that individuals aged 50 to 64 won't receive free flu vaccinations in the 2023/24 season. Moreover, the NHS plans to delay flu vaccine distribution to October, with the goal of enhancing protection for those aged 65 and older and other eligible groups during the winter months.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

Britain has become the first country to approve a Codiv-19 vaccine that targets both the original and Omicron variant of the virus. Medicines regulator MHRA approved the so-called bivalent vaccine made by US drug company Moderna as a booster for adults. The agency's decision was based on clinical trial data that showed the booster triggered "a strong immune response" against both Omicron (BA.1) and the original 2020 virus, it said. The MHRA also cited an exploratory analysis in which the shot was also found to generate a good immune response against the currently dominant Omicron offshoots BA.4 and BA.5. "The first generation of Covid-19 vaccines being used in the UK continue to provide important protection against the disease and save lives," MHRA chief executive June Raine said in a statement. "What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve."